最後更新 2024-11-05 08:31:13 (UTC+8)

基本分析

透過季節調整季營收,判斷美股整體趨勢,但注意股價有時候領先基本面的數據,應搭配其他領先指標判斷。

季營收趨勢 tooltip

季節調整季營收
季增率

8.5%


截至2024-06-30

基本資料

個股的基本資料,以及所屬的類股和產業。

公司介紹

業務介紹

特維製藥工業有限公司是一家製藥公司,在北美、歐洲和國際市場開發、製造、行銷和分銷仿製藥、專科藥品和生物製藥產品。該公司提供無菌產品、激素、高效藥物和細胞毒性物質,包括各種劑型,如片劑、膠囊、注射劑、吸入劑、液體、經皮貼劑、軟膏和乳膏。該公司還開發、製造和銷售活性藥物成分。此外,該公司專注於中樞神經系統、疼痛、呼吸系統和腫瘤學領域。其中樞神經系統產品包括Copaxone用於治療多發性硬化症復發型;AJOVY用於預防偏頭痛;AUSTEDO用於治療遲發性運動障礙和亨廷頓舞蹈病。該公司在呼吸系統市場的產品包括ProAir、QVAR、ProAir Digihaler、AirDuo Digihaler和ArmonAir Digihaler、BRALTUS、CINQAIR/CINQAERO、DuoResp Spiromax和AirDuo RespiClick/ArmonAir RespiClick,用於治療哮喘和慢性阻塞性肺病。其腫瘤學市場的產品包括Bendeka、Treanda、Granix、Trisenox、Lonquex和Tevagrastim/Ratiograstim。特維製藥工業有限公司與MedinCell合作,開發和商業化多種長效注射產品,包括用於治療精神分裂症患者的利培酮懸浮液。該公司成立於1901年,總部位於以色列特拉維夫-雅法。



Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

所屬產業

所屬類股
Healthcare
所屬產業
Drug Manufacturers - Specialty & Generic

警語

1. 資料僅供參考,不做任何獲利保證及特定股票與點位推薦建議。

2. 資料並不完整,需要完整資料請至相關網站索取。

3. 任何股市數據分析皆存在倖存者偏差。

warning